Compare Cassava Sciences Inc (FLNA) vs Icl Group Ltd (ICL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Icl Group Ltd — how do they compare? Cassava Sciences Inc trades at $1.07 (market cap $53.14M), while Icl Group Ltd trades at $5.07 (market cap $6.57B). The key difference: Icl Group Ltd is far larger — about 123.6× Cassava Sciences Inc's market cap, and Icl Group Ltd pays a 3.74% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | ICL | |
|---|---|---|
Market Cap | $53.14M | $6.57B |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $7.03 |
52-Week Low | $1.09 | $4.80 |
Enterprise Value | -$33.43M | $9.14B |
Dividend Yield | — | 3.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Filana Therapeutics (FLNA) trades at $1.09, down 5.22% on the day, reflecting persistent operational losses despite recent earnings beats. The stock exhibits a strong bearish technical signal, with moving averages and oscillators aligned negatively. Fundamentally, the company is in a pre-revenue biotech development phase, evidenced by significant negative cash flow from operations (-$32.25M in 2025) and deeply negative profitability metrics (ROE: -79.59%). Recent news highlights continued focus on its Tuberous Sclerosis Complex (TSC)-related epilepsy program.
The outlook is bifurcated: a bullish analyst consensus (8 Buy, 4 Hold, 0 Sell) suggests optimism for the clinical pipeline, while severe financial burn and bearish technicals present substantial near-term risk. Investment opportunity hinges entirely on successful drug development, with significant dilution or financing risk as the company funds operations. The stock is suitable only for high-risk investors comfortable with binary clinical outcomes.
ICL trades at $5.01, up 1.62% with bearish technical signals despite recent earnings beats. The company maintains stable cash flow with $1.06B from operations in 2025, though revenue has declined from $10B in 2022 to $7.15B in 2025. Recent $800M senior notes offering strengthens liquidity while analyst sentiment remains cautious with 100% hold ratings.
ICL faces margin compression with net income margin dropping to 3.52% amid rising costs. The stock's 24.29 P/E suggests full valuation relative to earnings growth. Key risks include raw material inflation and foreign exchange volatility, though improved debt management provides financial stability for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Icl Group Ltd
ICL Group Ltd is a manufacturer of products based on minerals. The firm is comprised of four segments: phosphate solutions, potash, industrial products, and innovative agriculture solutions (IAS). These segments all contribute to the company's development of agriculture, food, and engineered material products and services. The company mines and manufactures potash and phosphates to be used as ingredients in fertilizers and serve as a component in the pharmaceutical and food additives industries. It is also engaged in industrial additives and materials, including flame retardants, phosphate salts, specialty phosphate blends, purified phosphoric acid, electronic-grade specialty phosphoric acids. Its geographical segments are Europe, Asia, North & South America, and the Rest of the world.
Read more on ICL →
